Gastric Cancer – Pipeline Review, H1 2018

Global Markets Direct’s, ‘Gastric Cancer – Pipeline Review, H1 2018’, provides an overview of the Gastric Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Gastric Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Gastric Cancer and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Gastric Cancer

– The report reviews pipeline therapeutics for Gastric Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Gastric Cancer therapeutics and enlists all their major and minor projects

– The report assesses Gastric Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Gastric Cancer

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Gastric Cancer

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Gastric Cancer pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

3SBio Inc

AbbVie Inc

AbGenomics International Inc

Abion Inc

Adaptimmune Therapeutics Plc

ADC Therapeutics SA

Advenchen Laboratories LLC

Allist Shanghai Pharmaceutical Technology Co Ltd

Alteogen Inc

Ambrx Inc

amcure GmbH

Amgen Inc

ANP Technologies Inc

Antikor Biopharma Ltd

arGEN-X BV

Array BioPharma Inc

Asana BioSciences LLC

Aslan Pharmaceuticals Pte Ltd

Astellas Pharma Inc

AstraZeneca Plc

Atara Biotherapeutics Inc

Aurigene Discovery Technologies Ltd

Avipep Pty Ltd

Basilea Pharmaceutica Ltd

Bayer AG

BeiGene Ltd

Beijing Hanmi Pharmaceutical Co Ltd

Betta Pharmaceuticals Co Ltd

Bicycle Therapeutics Ltd

Biocon Ltd

Bioleaders Corp

BioLineRx Ltd

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Co

Camel-IDS NV

Cancer Prevention Pharmaceuticals Inc

CARsgen Therapeutics Ltd

Cascadian Therapeutics Inc

CBT Pharmaceuticals Inc

Celgene Corp

Celldex Therapeutics Inc

Cellestia Biotech AG

Celltrion Inc

Celon Pharma SA

Chipscreen Biosciences Ltd

Chugai Pharmaceutical Co Ltd

CSPC Pharmaceutical Group Limited

Curaxys SL

Cytori Therapeutics Inc

Daiichi Sankyo Co Ltd

Debiopharm International SA

Deciphera Pharmaceuticals LLC

Dr. Reddy's Laboratories Ltd

Eddingpharm Inc

Eisai Co Ltd

Eli Lilly and Co

EOS Biosciences Inc

Erytech Pharma SA

Esperance Pharmaceuticals Inc

Exelixis Inc

F-star Biotechnology Ltd

F. Hoffmann-La Roche Ltd

Fate Therapeutics Inc

Five Prime Therapeutics Inc

Frost Biologic Inc

Genelux Corp

Genentech Inc

Genmab A/S

Gilead Sciences Inc

GlaxoSmithKline Plc

Glenmark Pharmaceuticals Ltd

GlycoNex Inc

Glycotope GmbH

Halozyme Therapeutics Inc

Hanmi Pharmaceuticals Co Ltd

Harbin Gloria Pharmaceuticals Co Ltd

Horizon Pharma Plc

Humanigen Inc

Hummingbird Bioscience Pte Ltd

Hutchison MediPharma Ltd

Ignyta Inc

Ildong Pharmaceutical Co Ltd

Immunomedics Inc

Immunomet Therapeutics Inc

Incyte Corp

Inovio Pharmaceuticals Inc

Inspyr Therapeutics Inc

Intezyne Technologies Inc

Ipsen SA

Jiangsu Hengrui Medicine Co Ltd

Jiangsu Kanion Pharmaceutical Co Ltd

Johnson & Johnson

Jounce Therapeutics Inc

JW Pharmaceutical Corp

Kazia Therapeutics Ltd

Konruns Pharmaceutical Co Ltd

Kringle Pharma Inc

Kyowa Hakko Kirin Co Ltd

LATITUDE Pharmaceuticals Inc

Leap Therapeutics Inc

LegoChem Biosciences Inc

LinXis BV

Lycera Corp

MacroGenics Inc

Madrigal Pharmaceuticals Inc.

MaxiVAX SA

Mebiopharm Co Ltd

MedImmune LLC

Merck & Co Inc

Merck KGaA

Merrimack Pharmaceuticals Inc

Mersana Therapeutics Inc

Merus NV

Mirati Therapeutics Inc

Moderna Therapeutics Inc

Molecular Partners AG

Molecular Targeting Technologies Inc

Moleculin Biotech Inc

Mycenax Biotech Inc

NanoCarrier Co Ltd

Novartis AG

OBI Pharma Inc

Oncobiologics Inc

Oncolys BioPharma Inc

OncoMed Pharmaceuticals Inc

OncoResponse Inc

Ono Pharmaceutical Co Ltd

Opsona Therapeutics Ltd

Patrys Ltd

Pfizer Inc

Pharma Mar SA

Pieris Pharmaceuticals Inc

Prescient Therapeutics Ltd

Puma Biotechnology Inc

Redx Pharma Plc

Rhizen Pharmaceuticals SA

Richter Gedeon Nyrt

Sanofi

Scancell Holdings Plc

Selecta Biosciences Inc

SELLAS Life Sciences Group Inc

Sequella Inc

Shanghai Henlius Biotech Co Ltd

Shionogi & Co Ltd

Siamab Therapeutics Inc

Simcere Pharmaceutical Group

Sorrento Therapeutics Inc

Spectrum Pharmaceuticals Inc

Stelic Institute & Co

Supratek Pharma Inc

SynCore Biotechnology Co Ltd

Synthon Holdings BV

Taiho Pharmaceutical Co Ltd

Takeda Pharmaceutical Co Ltd

Takis Srl

Tarveda Therapeutics Inc

Terns Pharmaceuticals Inc

Tessa Therapeutics Pte Ltd

Transgene SA

United BioPharma Inc

Vaxon Biotech

Viracta Therapeutics Inc

Wuhan YZY Biopharma Co Ltd

XuanZhu Pharma Co Ltd

Zhejiang Jianfeng Group Company Ltd

Zymeworks Inc

Table of Contents

Table of Contents

Table of Contents 2

Introduction 9

Gastric Cancer Overview 10

Gastric Cancer Therapeutics Development 11

Gastric Cancer Therapeutics Assessment 47

Gastric Cancer Companies Involved in Therapeutics Development 67

Gastric Cancer Drug Profiles 142

Gastric Cancer Dormant Projects 1226

Gastric Cancer Discontinued Products 1236

Gastric Cancer Product Development Milestones 1239

Appendix 1250

List of Tables

List of Tables

Table 1: Number of Products under Development for Gastric Cancer, H1 2018 43

Table 2: Number of Products under Development by Companies, H1 2018 45

Table 3: Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018 46

Table 4: Number of Products under Development by Companies, H1 2018 (Contd..2), H1 2018 47

Table 5: Number of Products under Development by Companies, H1 2018 (Contd..3), H1 2018 48

Table 6: Number of Products under Development by Companies, H1 2018 (Contd..4), H1 2018 49

Table 7: Number of Products under Development by Companies, H1 2018 (Contd..5), H1 2018 50

Table 8: Number of Products under Development by Companies, H1 2018 (Contd..6), H1 2018 51

Table 9: Number of Products under Development by Companies, H1 2018 (Contd..7), H1 2018 52

Table 10: Number of Products under Development by Companies, H1 2018 (Contd..8), H1 2018 53

Table 11: Number of Products under Development by Companies, H1 2018 (Contd..9), H1 2018 54

Table 12: Number of Products under Development by Companies, H1 2018 (Contd..10), H1 2018 55

Table 13: Number of Products under Development by Universities/Institutes, H1 2018 56

Table 14: Products under Development by Companies, H1 2018 58

Table 15: Products under Development by Companies, H1 2018 (Contd..1), H1 2018 59

Table 16: Products under Development by Companies, H1 2018 (Contd..2), H1 2018 60

Table 17: Products under Development by Companies, H1 2018 (Contd..3), H1 2018 61

Table 18: Products under Development by Companies, H1 2018 (Contd..4), H1 2018 62

Table 19: Products under Development by Companies, H1 2018 (Contd..5), H1 2018 63

Table 20: Products under Development by Companies, H1 2018 (Contd..6), H1 2018 64

Table 21: Products under Development by Companies, H1 2018 (Contd..7), H1 2018 65

Table 22: Products under Development by Companies, H1 2018 (Contd..8), H1 2018 66

Table 23: Products under Development by Companies, H1 2018 (Contd..9), H1 2018 67

Table 24: Products under Development by Companies, H1 2018 (Contd..10), H1 2018 68

Table 25: Products under Development by Companies, H1 2018 (Contd..11), H1 2018 69

Table 26: Products under Development by Companies, H1 2018 (Contd..12), H1 2018 70

Table 27: Products under Development by Companies, H1 2018 (Contd..13), H1 2018 71

Table 28: Products under Development by Companies, H1 2018 (Contd..14), H1 2018 72

Table 29: Products under Development by Companies, H1 2018 (Contd..15), H1 2018 73

Table 30: Products under Development by Companies, H1 2018 (Contd..16), H1 2018 74

Table 31: Products under Development by Companies, H1 2018 (Contd..17), H1 2018 75

Table 32: Products under Development by Companies, H1 2018 (Contd..18), H1 2018 76

Table 33: Products under Development by Universities/Institutes, H1 2018 77

Table 34: Products under Development by Universities/Institutes, H1 2018 (Contd..1), H1 2018 78

Table 35: Number of Products by Stage and Target, H1 2018 80

Table 36: Number of Products by Stage and Target, H1 2018 (Contd..1), H1 2018 81

Table 37: Number of Products by Stage and Target, H1 2018 (Contd..2), H1 2018 82

Table 38: Number of Products by Stage and Target, H1 2018 (Contd..3), H1 2018 83

Table 39: Number of Products by Stage and Target, H1 2018 (Contd..4), H1 2018 84

Table 40: Number of Products by Stage and Target, H1 2018 (Contd..5), H1 2018 85

Table 41: Number of Products by Stage and Target, H1 2018 (Contd..6), H1 2018 86

Table 42: Number of Products by Stage and Mechanism of Action, H1 2018 88

Table 43: Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..1), H1 2018 89

Table 44: Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..2), H1 2018 90

Table 45: Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..3), H1 2018 91

Table 46: Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..4), H1 2018 92

Table 47: Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..5), H1 2018 93

Table 48: Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..6), H1 2018 94

Table 49: Number of Products by Stage and Route of Administration, H1 2018 96

Table 50: Number of Products by Stage and Molecule Type, H1 2018 98

Table 51: Gastric Cancer Pipeline by 3SBio Inc, H1 2018 99

Table 52: Gastric Cancer Pipeline by AbbVie Inc, H1 2018 100

Table 53: Gastric Cancer Pipeline by AbGenomics International Inc, H1 2018 100

Table 54: Gastric Cancer Pipeline by Abion Inc, H1 2018 100

Table 55: Gastric Cancer Pipeline by Adaptimmune Therapeutics Plc, H1 2018 101

Table 56: Gastric Cancer Pipeline by ADC Therapeutics SA, H1 2018 101

Table 57: Gastric Cancer Pipeline by Advenchen Laboratories LLC, H1 2018 102

Table 58: Gastric Cancer Pipeline by Allist Shanghai Pharmaceutical Technology Co Ltd, H1 2018 102

Table 59: Gastric Cancer Pipeline by Alteogen Inc, H1 2018 102

Table 60: Gastric Cancer Pipeline by Ambrx Inc, H1 2018 103

Table 61: Gastric Cancer Pipeline by amcure GmbH, H1 2018 103

Table 62: Gastric Cancer Pipeline by Amgen Inc, H1 2018 104

Table 63: Gastric Cancer Pipeline by ANP Technologies Inc, H1 2018 104

Table 64: Gastric Cancer Pipeline by Antikor Biopharma Ltd, H1 2018 104

Table 65: Gastric Cancer Pipeline by arGEN-X BV, H1 2018 105

Table 66: Gastric Cancer Pipeline by Array BioPharma Inc, H1 2018 105

Table 67: Gastric Cancer Pipeline by Asana BioSciences LLC, H1 2018 106

Table 68: Gastric Cancer Pipeline by Aslan Pharmaceuticals Pte Ltd, H1 2018 106

Table 69: Gastric Cancer Pipeline by Astellas Pharma Inc, H1 2018 107

Table 70: Gastric Cancer Pipeline by AstraZeneca Plc, H1 2018 107

Table 71: Gastric Cancer Pipeline by Atara Biotherapeutics Inc, H1 2018 108

Table 72: Gastric Cancer Pipeline by Aurigene Discovery Technologies Ltd, H1 2018 108

Table 73: Gastric Cancer Pipeline by Avipep Pty Ltd, H1 2018 108

Table 74: Gastric Cancer Pipeline by Basilea Pharmaceutica Ltd, H1 2018 109

List of Figures

List of Figures

Figure 1: Number of Products under Development for Gastric Cancer, H1 2018 43

Figure 2: Number of Products under Development by Companies, H1 2018 44

Figure 3: Number of Products under Development by Universities/Institutes, H1 2018 56

Figure 4: Number of Products by Top 10 Targets, H1 2018 79

Figure 5: Number of Products by Stage and Top 10 Targets, H1 2018 79

Figure 6: Number of Products by Top 10 Mechanism of Actions, H1 2018 87

Figure 7: Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018 87

Figure 8: Number of Products by Top 10 Routes of Administration, H1 2018 95

Figure 9: Number of Products by Stage and Top 10 Routes of Administration, H1 2018 95

Figure 10: Number of Products by Top 10 Molecule Types, H1 2018 97

Figure 11: Number of Products by Stage and Top 10 Molecule Types, H1 2018 97

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports